Tandem Diabetes Care, Inc. (TNDM - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $53.13–$64.89 in the past one-month time frame, witnessed a sharp increase yesterday.
The stock gained after the company announced that it intends to develop and commercialize integrated diabetes solutions by combining Abbott's glucose sensing technology with its innovative insulin delivery systems.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Tandem currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Tandem Diabetes Care, Inc. Price
Investors interested in the Medical – Instruments industry may consider Cantel Medical Corp. (CMD - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is TNDM going up? Or down? Predict to see what others think: Up or Down
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Download Free Report Now >>